Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 9/20 | 0.66 |
| ▸ | KDR | P35968 | 9/20 | 0.65 |
| ▸ | AURKA | O14965 | 3/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.62 |
| ▸ | FLT4 | P35916 | 3/20 | 0.62 |
| ▸ | BRAF | P15056 | 2/20 | 0.62 |
| ▸ | RAF1 | P04049 | 2/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.62 |
| ▸ | TEK | Q02763 | 2/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.61 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 5/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17278101 | 1.00 | SRC (0.66) | SRCKDRAURKAAURKBFLT4 | |
| SCHEMBL7209612 | 0.95 | EGFR (0.62) | SRCKDRAURKAAURKBFLT4 | |
| SCHEMBL19258107 | 0.90 | KDR (0.73) | SRCKDRAURKAAURKBFLT4 | |
| SCHEMBL19258108 | 0.89 | KDR (0.63) | SRCKDRAURKAAURKBFLT4 | |
| SCHEMBL4376854 | 0.88 | SRC (0.65) | SRCKDRBRAFRAF1EGFR | |
| SCHEMBL16692932 | 0.88 | BRAF (0.70) | SRCKDRFLT4BRAFRAF1 | |
| SCHEMBL19258554 | 0.87 | BRAF (0.63) | SRCKDRAURKAAURKBFLT4 | |
| SCHEMBL4378957 | 0.86 | SRC (0.61) | SRCKDRAURKAAURKBFLT4 | |
| SCHEMBL5501376 | 0.86 | KDR (0.66) | SRCKDRAURKAAURKBFLT4 | |
| SCHEMBL4379508 | 0.86 | SRC (0.58) | SRCKDRAURKAAURKBFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| EP-1381599-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | EP | disclosed |
| US-7223756-B2 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7141577-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| US-6184225-B1 | ENDOTHELIAL GROWTH FACTOR INHIBITORS, ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 2001-02-06 | — | — | US | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0880508-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030035-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | SRC 1517/4885KDR 3/4885AURKA 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.